Kang Xianhui, Wang Yijian, Liu Pan, Huang Baojun, Zhou Baofeng, Lu Shufang, Geng Wujun, Tang Hongli
Department of Pain, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.
Department of Anesthesiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.
Cancers (Basel). 2023 Jan 6;15(2):396. doi: 10.3390/cancers15020396.
Glioma refers to a tumor that is derived from brain glial stem cells or progenitor cells and is the most common primary intracranial tumor. Due to its complex cellular components, as well as the aggressiveness and specificity of the pathogenic site of glioma, most patients with malignant glioma have poor prognoses following surgeries, radiotherapies, and chemotherapies. In recent years, an increasing amount of research has focused on the use of CRISPR/Cas9 gene-editing technology in the treatment of glioma. As an emerging gene-editing technology, CRISPR/Cas9 utilizes the expression of certain functional proteins to repair tissues or treat gene-deficient diseases and could be applied to immunotherapies through the expression of antigens, antibodies, or receptors. In addition, some research also utilized CRISPR/Cas9 to establish tumor models so as to study tumor pathogenesis and screen tumor prognostic targets. This paper mainly discusses the roles of CRISPR/Cas9 in the treatment of glioma patients, the exploration of the pathogenesis of neuroglioma, and the screening targets for clinical prognosis. This paper also raises the future research prospects of CRISPR/Cas9 in glioma, as well as the opportunities and challenges that it will face in clinical treatment in the future.
胶质瘤是指起源于脑胶质干细胞或祖细胞的肿瘤，是最常见的原发性颅内肿瘤。由于其细胞成分复杂，以及胶质瘤致病部位的侵袭性和特异性，大多数恶性胶质瘤患者在手术、放疗和化疗后的预后较差。近年来，越来越多的研究集中在CRISPR/Cas9基因编辑技术在胶质瘤治疗中的应用。作为一种新兴的基因编辑技术，CRISPR/Cas9利用某些功能蛋白的表达来修复组织或治疗基因缺陷疾病，并可通过表达抗原、抗体或受体应用于免疫治疗。此外，一些研究还利用CRISPR/Cas9建立肿瘤模型，以研究肿瘤发病机制并筛选肿瘤预后靶点。本文主要探讨CRISPR/Cas9在胶质瘤患者治疗中的作用、神经胶质瘤发病机制的探索以及临床预后的筛选靶点。本文还提出了CRISPR/Cas9在胶质瘤中的未来研究前景，以及其未来在临床治疗中将要面临的机遇和挑战。
